A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Allergan

Status: Completed

Conditions: Ocular Hypertension

Treatments: Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).; Drug: Loteprednol etabonate ophthalmic suspension 0.5%

Study type: Observational

Funder types: Industry

Identifiers

NCT00834171

MA-RES-08-003

Details and patient eligibility

About

Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient who experienced an IOP spike while using Lotemax or Zylet will be included

Exclusion criteria

• N/A

Trial design

50 participants in 2 patient groups

1

Description:

Loteprednol etabonate ophthalmic suspension 0.5%

Treatment:

Drug: Loteprednol etabonate ophthalmic suspension 0.5%

2

Description:

Loteprednol etabonate (0.5%) and tobramycin (0.3%)

Treatment:

Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).